Molecular Partners AG (OTCMKTS:MLLCF – Get Free Report) traded up 90.2% during mid-day trading on Thursday . The stock traded as high as $4.85 and last traded at $4.85. 150 shares changed hands during mid-day trading, a decline of 82% from the average session volume of 831 shares. The stock had previously closed at $2.55.
Molecular Partners Stock Up 90.2%
The firm’s 50 day moving average price is $2.58 and its 200-day moving average price is $2.91.
Molecular Partners Company Profile
Molecular Partners AG is a clinical-stage biotechnology company headquartered in Zurich, Switzerland, specializing in the development of novel protein therapeutics based on its proprietary DARPin® (Designed Ankyrin Repeat Proteins) platform. The company’s pipeline focuses on precision molecules engineered for oncology and immuno-inflammatory diseases, as well as antiviral and anti-infective applications. By leveraging the modular nature of DARPin® science, Molecular Partners designs small, highly stable binding proteins that can engage multiple targets simultaneously, potentially improving efficacy and safety profiles over conventional antibody approaches.
Founded in 2004 by Professor Andreas Plückthun at the University of Zurich, Molecular Partners has advanced several clinical-stage candidates through Phase 1 and Phase 2 trials.
Recommended Stories
- Five stocks we like better than Molecular Partners
- 3 Stocks Rallying on Micron’s Price Boost: Substance or Hype?
- Snowflake and the Snowballing Impact of its AI Flywheel
- AI’s Biggest Bottleneck Could Make These 2 Stocks Soar
- These 3 Beaten-Down Stocks Just Saw $25 Million in Insider Buying
Receive News & Ratings for Molecular Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Partners and related companies with MarketBeat.com's FREE daily email newsletter.
